By Daniella Parra
March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said.
The company said the therapy employs a proprietary CAR design that enables selective targeting of malignant cells without additional genetic manipulation and minimizes T-cell fratricide, early evidence suggesting complete clearance of CD5-positive disease in most patients treated.
“What we’re seeing with MB-105 is truly remarkable for this patient population,” Dr. Swami Iyer, Principal Investigator of the study, said. “These patients had exhausted multiple treatment options, yet we achieved responses in every evaluable patient with manageable side effects. The robust CAR-T cell expansion and persistence we observed suggest this approach could fundamentally change how we treat relapsed and refractory T-cell lymphomas.”
READ MORE
NYSE Firesides Scheduled Dec 9, 2025 & Feb 3, 2026
Never Miss our Weekly Highlights HERE
